Eplerenone, an aldosterone antagonist, reduces hospitalization and death in heart failure patients with NYHA class II and an ejection fraction of less than 30%

Intern Emerg Med. 2011 Oct;6(5):453-4. doi: 10.1007/s11739-011-0661-0. Epub 2011 Jul 17.

Authors

Simone Birocchi¹, Giulia Carla Luisa Cernuschi; Gruppo di Autoformazione Metodologica (GrAM)

Affiliation

¹ Medicina Interna 2, Ospedale L. Sacco, Università degli Studi di Milano, Via G.B. Grassi, 74, 20157 Milan, MI, Italy. simone.birocchi@studenti.unimi.it

PMID: 21769601
DOI: 10.1007/s11739-011-0661-0

No abstract available

MeSH terms

Eplerenone
Heart Failure / classification
Heart Failure / drug therapy*
Heart Failure / mortality*
Heart Failure / physiopathology
Hospitalization / statistics & numerical data*
Humans
Mineralocorticoid Receptor Antagonists / therapeutic use*
Randomized Controlled Trials as Topic
Severity of Illness Index
Spironolactone / analogs & derivatives*
Spironolactone / therapeutic use
Stroke Volume

Substances

Mineralocorticoid Receptor Antagonists
Spironolactone
Eplerenone